{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:53Z","timestamp":1782337253220,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R325-A18705"],"award-info":[{"award-number":["R325-A18705"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R374-A22191"],"award-info":[{"award-number":["R374-A22191"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01CA257679-01A1"],"award-info":[{"award-number":["1U01CA257679-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002918","name":"Gentofte Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005111","name":"Copenhagen University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100219","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:27:09Z","timestamp":1773746829000},"page":"100219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD20 negativity at the start of second-line therapy predicts a shorter overall survival in B-cell lymphomas"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4225-3119","authenticated-orcid":false,"given":"Sanaz Mehdi","family":"Gholy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2353-2528","authenticated-orcid":false,"given":"Torger\u00f0","family":"Ranad\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-5409","authenticated-orcid":false,"given":"Olafur Birgir","family":"Davidsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-5693","authenticated-orcid":false,"given":"Ragnar P\u00e9tur","family":"Kristj\u00e1nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-0354","authenticated-orcid":false,"given":"Tereza Fait","family":"Kadlec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-5775","authenticated-orcid":false,"given":"Noomi","family":"Vainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8348-1907","authenticated-orcid":false,"given":"Andreas","family":"Katsimigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"Werling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8549-7409","authenticated-orcid":false,"given":"Emil","family":"Kyvsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-1173","authenticated-orcid":false,"given":"Simon","family":"Husby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-3098","authenticated-orcid":false,"given":"Caspar","family":"da Cunha-Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-9414","authenticated-orcid":false,"given":"Klaus","family":"Rostgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-4086","authenticated-orcid":false,"given":"Peter","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4436-6798","authenticated-orcid":false,"given":"Henrik","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-8106","authenticated-orcid":false,"given":"Christian","family":"Brieghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-4591","authenticated-orcid":false,"given":"Jojo Biel-Nielsen","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"JUN","key":"10.1016\/j.bneo.2026.100219_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab: the world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100219_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-017-0088-5","article-title":"Diagnosis and treatment of CD20 negative B cell lymphomas","volume":"5","author":"Katchi","year":"2017","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.bneo.2026.100219_bib3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.14740\/jh1341","article-title":"Retrospective study of CD20 expression loss in relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"13","author":"Marshalek","year":"2024","journal-title":"J Hematol"},{"issue":"13","key":"10.1016\/j.bneo.2026.100219_bib4","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/bloodadvances.2018017673","article-title":"Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study","volume":"2","author":"Madsen","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2026.100219_bib5","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","article-title":"Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis","volume":"11","author":"Luo","year":"2021","journal-title":"Sci Rep"},{"issue":"10438","key":"10.1016\/j.bneo.2026.100219_bib6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.bneo.2026.100219_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100096","article-title":"Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20\u00d7CD3 antibodies","volume":"2","author":"Kyvsgaard","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"20","key":"10.1016\/j.bneo.2026.100219_bib8","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100219_bib9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1349-7006.2012.02307.x","article-title":"Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment","volume":"103","author":"Miyoshi","year":"2012","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.bneo.2026.100219_bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100219_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1078-0432.CCR-11-1429","article-title":"Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma","volume":"18","author":"Tsai","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bneo.2026.100219_bib12","first-page":"331","article-title":"CD20 expression and effects on outcome of relapsed\/refractory diffuse large B-cell lymphoma after treatment with rituximab","volume":"19","author":"Rasheed","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.bneo.2026.100219_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-023-00432-z","article-title":"The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"12","author":"Lu","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100219_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100219_bib15","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","article-title":"Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis","volume":"4","author":"Lepp\u00e4","year":"2020","journal-title":"Blood Adv"},{"issue":"10216","key":"10.1016\/j.bneo.2026.100219_bib16","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.bneo.2026.100219_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bneo.2026.100219_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100219_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100219_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7173","article-title":"Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy","volume":"13","author":"Sineshaw","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100219_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR T cells: dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.bneo.2026.100219_bib22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.bneo.2026.100219_bib23","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood.2024025772","article-title":"Emerging biomarkers for CD3\u00d7CD20 bispecific antibodies in lymphoma","volume":"145","author":"Lewis","year":"2025","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2026.100219_bib24","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100219_bib25","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/bjh.20104","article-title":"Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies","volume":"206","author":"Harrysson","year":"2025","journal-title":"Br J Haematol"},{"issue":"10306","key":"10.1016\/j.bneo.2026.100219_bib26","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.bneo.2026.100219_bib27","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2024.012","article-title":"CAR T-cell therapy for follicular lymphomas","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"4","key":"10.1016\/j.bneo.2026.100219_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100131","article-title":"Current landscape of frontline and relapsed follicular lymphoma trials","volume":"2","author":"Ng","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"13","key":"10.1016\/j.bneo.2026.100219_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132239","article-title":"Next-generation therapies in mantle cell lymphoma (MCL): the evolving landscape in treatment of relapse\/refractory after CAR-T cells","volume":"17","author":"Boccellato","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"10441","key":"10.1016\/j.bneo.2026.100219_bib30","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.bneo.2026.100219_bib31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.bneo.2026.100219_bib32","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.22.02327","article-title":"Randomized phase III trial evaluating subcutaneous rituximab for the first-line treatment of low\u2013tumor burden follicular lymphoma: results of a LYSA study","volume":"41","author":"Cartron","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bneo.2026.100219_bib33","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2026.100219_bib34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.2023023525","article-title":"Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study","volume":"144","author":"Malinverni","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100219_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100128","article-title":"Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study","volume":"2","author":"Trab","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"3","key":"10.1016\/j.bneo.2026.100219_bib36","first-page":"710","article-title":"Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma","volume":"4","author":"Michot","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"8","key":"10.1016\/j.bneo.2026.100219_bib37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell\u2013redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100219_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ajh.27601","article-title":"NOTCH1 mutations are associated with therapy-resistance in patients with B-cell lymphoma treated with CD20xCD3 bispecific antibodies","volume":"100","author":"Kyvsgaard","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2026.100219_bib39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CLEP.S479672","article-title":"The Danish Lymphoid Cancer Research (DALY-CARE) data resource: the basis for developing data-driven hematology","volume":"17","author":"Brieghel","year":"2025","journal-title":"Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100219_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157999","article-title":"The Danish National Lymphoma Registry: coverage and data quality","volume":"11","author":"Arboe","year":"2016","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.bneo.2026.100219_bib41","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100219_bib42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100219_bib43","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100219_bib44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100219_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70172","article-title":"Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer","volume":"9","author":"Brieghel","year":"2025","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.bneo.2026.100219_bib46","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/bloodadvances.2024014404","article-title":"Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study","volume":"9","author":"Tolley","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.bneo.2026.100219_bib47","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2026.100219_bib48","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.bneo.2026.100219_bib49","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2026.100219_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100219_bib51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2023-173951","article-title":"Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:27:13Z","timestamp":1779294433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328026000300"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100219","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD20 negativity at the start of second-line therapy predicts a shorter overall survival in B-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100219"}}